Want to see FR:VLA full AI Analyst Report?
VLA Stock Chart & Stats
€2.84
€0.04(1.75%)
At close: 4:00 PM EDT
€2.84
€0.04(1.75%)
Day’s Range― - ―
52-Week Range€2.03 - €5.15
Previous CloseN/A
Volume117.56K
Average Volume (3M)358.14K
Market Cap
€441.12M
Enterprise Value€516.36M
Total Cash (Recent Filing)€121.53M
Total Debt (Recent Filing)€210.23M
Price to Earnings (P/E)―
Beta1.66
Next Earnings
Nov 12, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares Outstanding189,771,240
10 Day Avg. Volume424,822
30 Day Avg. Volume358,141
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)5.89
Price to Sales (P/S)3.58
P/FCF Ratio-10.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.44
Revenue Forecast (FY)€151.44M
Bulls Say, Bears Say
Bulls Say
Lyme Vaccine PipelinePositive clinical efficacy and advancing EMA review could create a differentiated late-stage growth asset beyond Valneva’s current products. If approval is achieved, the Lyme program may broaden commercial reach and increase the strategic value of Valneva’s vaccine platform.
Restructuring And Cost DisciplineThe restructuring addresses the company’s cost base through workforce reductions and project reprioritization. Although it incurred a one-time charge, expected recurring savings and better cash flow could improve operating leverage and support progress toward financial self-sufficiency.
IXCHIQ Public-health AccessButantan’s approved local manufacturing and planned public-health incorporation provide IXCHIQ with a potentially durable route into an endemic market. Broader access and real-world vaccination activity can strengthen commercialization capabilities beyond travel-focused demand.
Bears Say
Revenue ContractionThe sharp H1 revenue decline shows that Valneva’s existing commercial base is not currently delivering consistent growth. Lower sales across core products reduce operating scale, make fixed costs harder to absorb, and increase reliance on future pipeline or contract-led expansion.
Persistent Losses And Cash BurnLarge operating and EBITDA losses, together with continued use of cash in operations, indicate that the business has not yet achieved sustainable self-funding. Ongoing burn can constrain investment in the pipeline and increase dependence on financing while profitability remains uncertain.
Weakened Balance SheetA shrinking equity base and materially higher debt-to-equity ratio reduce financial resilience while losses persist. Greater leverage can limit flexibility to fund development, absorb further setbacks, or bridge the company through a prolonged period before new products contribute meaningful earnings.
Valneva News
VLA FAQ
What was Valneva SE’s price range in the past 12 months?
Valneva SE lowest stock price was €2.03 and its highest was €5.15 in the past 12 months.
What is Valneva SE’s market cap?
Valneva SE’s market cap is €441.12M.
When is Valneva SE’s upcoming earnings report date?
Valneva SE’s upcoming earnings report date is Nov 12, 2026 which is in 19 days.
How were Valneva SE’s earnings last quarter?
Valneva SE released its earnings results on Aug 13, 2026. The company reported -€0.17 earnings per share for the quarter, missing the consensus estimate of -€0.089 by -€0.081.
Is Valneva SE overvalued?
According to Wall Street analysts Valneva SE’s price is currently Overvalued.
Does Valneva SE pay dividends?
Valneva SE does not currently pay dividends.
What is Valneva SE’s EPS estimate?
Valneva SE’s EPS estimate is -0.09.
How many shares outstanding does Valneva SE have?
Valneva SE has 189,771,240 shares outstanding.
What happened to Valneva SE’s price movement after its last earnings report?
Valneva SE reported an EPS of -€0.17 in its last earnings report, missing expectations of -€0.089. Following the earnings report the stock price went down -0.203%.
Which hedge fund is a major shareholder of Valneva SE?
Currently, no hedge funds are holding shares in FR:VLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valneva SE
Valneva SE is a specialized biotechnology company focused on developing and bringing to market preventative vaccines for infectious diseases with significant unmet medical needs. Their commercial offerings for travelers include IXIARO, a vaccine against Japanese encephalitis, and DUKORAL, an oral vaccine designed to protect against diarrhea caused by Vibrio cholera and specific heat-labile toxin-producing Enterotoxigenic Escherichia coli. The company also progressed VLA2001, a vaccine candidate targeting SARS-CoV-2. In its development pipeline, Valneva has VLA15, a Lyme disease vaccine candidate that has concluded Phase II clinical trials, and VLA1553, a chikungunya virus vaccine candidate currently undergoing Phase III evaluation. The company distributes its products across the United States, Canada, various European nations including Germany, Austria, the Nordics, and the United Kingdom, as well as other global markets. Valneva SE has established strategic partnerships, notably with Pfizer, Inc. for the joint development and commercialization of its Lyme disease vaccine, and with Instituto Butantan for the creation, manufacturing, and marketing of a single-shot chikungunya vaccine. The company was established in 1998 and operates from its headquarters in Saint-Herblain, France.